PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new...
Company Optimizing Capital Allocation Strategy, Expanding De Novo Locations, Deepening Referral Networks, and Advancing a Healthcare System Focused M&A StrategyCINCINNATI,...
KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company...
BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and...
ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a...
MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies...
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and...
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to...
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325...
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase...
FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration...
Tilray Expands Their Health-Focused Food and Beverage Portfolio with the Reintroduction of a Beloved Energy Drink, Hi*Ball Energy NEW YORK,...
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital...
Company Appoints Medical Device and Healthcare Industry Veteran with 20 Years of ExperienceEXTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) --...
Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity...
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU,...
Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative...
TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released the English version of the...
SEATTLE, March 24, 2025 /PRNewswire/ -- The surge in online supplement sales has led to a troubling rise in counterfeit...
Achieves International Recognition with HIMSS Award for Excellence in Smart Healthcare TAOYUAN, March 23, 2025 /PRNewswire/ -- As the demand...